Literature DB >> 16462151

Advances in the recognition of tubal intraepithelial carcinoma: applications to cancer screening and the pathogenesis of ovarian cancer.

Yonghee Lee1, Fabiola Medeiros, David Kindelberger, Michael J Callahan, Michael G Muto, Christopher P Crum.   

Abstract

Prophylactic salpingo-oophorectomies from women with BRCA mutations (BRCA+) have identified the tube as a frequent site of early pelvic serous carcinoma (tubal intraepithelial carcinoma [TIC]). These observations have implications for both the early recognition of pelvic serous carcinoma in susceptible women and determining the ultimate site of origin for pelvic serous carcinomas. Moreover, the unique pathology of TIC has shifted attention from the more exuberant proliferations mentioned in prior studies to a spectrum of neoplastic atypias that can be morphologically subtle. This review addresses a multitude of epithelial changes; benign, malignant, and an intriguing third group, which we term "p53 signatures," is found in benign, nonciliated epithelium and stain intensely positive for p53. Understanding all 3 is important for the proper management of women undergoing prophylactic salpingo-oophorectomy and possibly formulating an integrated model for the pathogenesis of serous carcinoma in the reproductive tract. A protocol for sectioning and extensively examining the fimbriated end (SEE-FIM), and its rationale, is described.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16462151     DOI: 10.1097/01.pap.0000201826.46978.e5

Source DB:  PubMed          Journal:  Adv Anat Pathol        ISSN: 1072-4109            Impact factor:   3.875


  33 in total

1.  Shortened telomeres in serous tubal intraepithelial carcinoma: an early event in ovarian high-grade serous carcinogenesis.

Authors:  Elisabetta Kuhn; Alan Meeker; Tian-Li Wang; Ann Smith Sehdev; Robert J Kurman; Ie-Ming Shih
Journal:  Am J Surg Pathol       Date:  2010-06       Impact factor: 6.394

2.  Mucosal carcinoma of the fallopian tube coexists with ovarian cancer of serous subtype only: a study of Japanese cases.

Authors:  Daichi Maeda; Satoshi Ota; Yutaka Takazawa; Kenichi Ohashi; Masaya Mori; Tetsuo Imamura; Shunsuke Nakagawa; Tetsu Yano; Yuji Taketani; Masashi Fukayama
Journal:  Virchows Arch       Date:  2010-09-25       Impact factor: 4.064

3.  Peritoneal washing cytology in patients with BRCA1 or BRCA2 mutations undergoing risk-reducing salpingo-oophorectomies: a 10-year experience and reappraisal of its clinical utility.

Authors:  G Landon; J Stewart; M Deavers; K Lu; N Sneige
Journal:  Gynecol Oncol       Date:  2012-03-13       Impact factor: 5.482

4.  Long term follow up of BRCA1 and BRCA2 mutation carriers with unsuspected neoplasia identified at risk reducing salpingo-oophorectomy.

Authors:  C B Powell; E M Swisher; I Cass; J McLennan; B Norquist; R L Garcia; J Lester; B Y Karlan; L Chen
Journal:  Gynecol Oncol       Date:  2013-02-04       Impact factor: 5.482

Review 5.  The role of the fallopian tube in the origin of ovarian cancer.

Authors:  Britt K Erickson; Michael G Conner; Charles N Landen
Journal:  Am J Obstet Gynecol       Date:  2013-04-10       Impact factor: 8.661

6.  A case of non-invasive serous adenocarcinoma at unilateral fimbria with spread to the peritoneal/uterine cavity: case report.

Authors:  Yuki Fukumura; Akiko Masaoka; Toshio Naito; Miki Kimura; Takashi Yao
Journal:  Diagn Pathol       Date:  2009-12-05       Impact factor: 2.644

7.  Perceptions of risk and reward in BRCA1 and BRCA2 mutation carriers choosing salpingectomy for ovarian cancer prevention.

Authors:  Talayeh S Ghezelayagh; Lauren E Stewart; Barbara M Norquist; Deborah J Bowen; Vivian Yu; Kathy J Agnew; Kathryn P Pennington; Elizabeth M Swisher
Journal:  Fam Cancer       Date:  2020-02-24       Impact factor: 2.375

Review 8.  Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer.

Authors:  Christopher P Crum; Ronny Drapkin; David Kindelberger; Fabiola Medeiros; Alexander Miron; Yonghee Lee
Journal:  Clin Med Res       Date:  2007-03

Review 9.  Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management.

Authors:  Henry T Lynch; Murray Joseph Casey; Carrie L Snyder; Chhanda Bewtra; Jane F Lynch; Matthew Butts; Andrew K Godwin
Journal:  Mol Oncol       Date:  2009-02-21       Impact factor: 6.603

10.  The preclinical natural history of serous ovarian cancer: defining the target for early detection.

Authors:  Patrick O Brown; Chana Palmer
Journal:  PLoS Med       Date:  2009-07-28       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.